Table 1 The approved indications of α-PD-1/PD-L1 antibodies in the globe
From: Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Drugs | Approval | SC | NSCLC | SCLC | RCC | HL | HNC | UC | CRC | HCC | ESC | MPM | GC | GEJC | TNBC | BC | CC | EC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nivolumab | 2014-US 2015-EU 2018-PRC | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | – | – | – | – |
Pembrolizumab | 2014-US 2015-EU 2018-PRC | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | – | √ | √ | √ | √ | √ | √ |
Cemiplimab | 2018-US 2019-EU | √ | √ | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Toripalimab | 2018-PRC | √ | – | – | – | – | √ | √ | – | – | – | – | – | – | – | – | – | – |
Sintilimab | 2018-PRC | – | √ | – | – | √ | – | – | – | √ | – | – | – | – | – | – | – | – |
Camrelizumab | 2019-PRC | – | √ | – | – | √ | √ | – | – | √ | √ | – | – | – | – | – | – | – |
Tislelizumab | 2019-PRC | – | √ | – | – | √ | – | √ | – | – | – | – | – | – | – | – | – | – |
Zimberelimab | 2021-PRC | – | – | – | – | √ | – | – | – | – | – | – | – | – | – | – | – | – |
Prolgolimab | 2020-RU | √ | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Dostarlimab | 2021-US 2021-EU | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | √ |
Atezolizumab | 2016-US 2017-EU 2020-PRC | √ | √ | √ | – | – | – | √ | – | √ | – | – | – | – | √ | – | – | – |
Durvalumab | 2017-US 2018-EU 2019-PRC | – | √ | √ | – | – | – | – | – | – | – | – | – | – | – | √ | – | – |
Avelumab | 2017-US 2017-EU | √ | – | – | √ | – | – | √ | – | – | – | – | – | – | – | – | – | – |